Allarity Therapeutics (ALLR) vs Citius Pharmaceuticals (CTXR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Allarity Therapeutics (ALLR) has outperformed Citius Pharmaceuticals (CTXR) over the past year, losing 25.9% versus a loss of 55.4%. Citius Pharmaceuticals is the larger company by market cap ($14.0 million vs $12.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLR | CTXR |
|---|---|---|
| Share price | $0.785 | $0.5085 |
| Market cap | $12.56M | $13.96M |
| 1-day change | -9.25% | +2.27% |
| YTD return | -27.31% | -34.56% |
| 1-year return | -25.94% | -55.39% |
| 5-year return | — | -98.79% |
| EPS (TTM) | $-0.79 | $-1.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $320.00K | — |
| Net income (latest FY) | $-11.23M | $-39.74M |
| Operating margin | -3939.06% | — |
| Net margin | -3509.69% | — |
| 52-week high | $1.84 | $1.54 |
| 52-week low | $0.769 | $0.37 |
| Distance from 52-week high | -57.34% | -66.98% |
| Analyst consensus | none | none |
| Avg. price target upside | +1301.27% | +686.63% |
| Average volume | 131.74K | 275.44K |
| Shares outstanding | 16.00M | 27.45M |
| Employees | 7 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALLR has outperformed CTXR by 29.5 percentage points over the past year.
About Allarity Therapeutics
ALLR stock →Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company develops drugs for the personalized treatment of cancer using drug-specific companion diagnostics generated by its proprietary drug response predictor (DRP) technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
ALLR vs CTXR FAQ
Which is bigger, Allarity Therapeutics or Citius Pharmaceuticals?
Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.96M compared with $12.56M for Allarity Therapeutics (ALLR).
Which stock has performed better over the past year, ALLR or CTXR?
ALLR returned -25.94% over the past 12 months, compared with -55.39% for CTXR (price return, excluding dividends). Past performance does not predict future results.
Are Allarity Therapeutics and Citius Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.